(News Bulletin 247) – Bayer today announced that it has partnered with Acuitas Therapeutics, a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapies.
Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spherical drug delivery bodies that can be equipped with therapeutic payloads for intracellular delivery.
Acuitas’ technology is used in many vaccines and therapies in clinical development and has also been used in some of the COVID-19 vaccines that have been approved and given to people in 180 countries.
“Access to cutting-edge LNP technology through this collaboration will give impetus to our gene-editing efforts for the benefit of patients,” said Friedemann Janus, Acting Head of Business Development and Grant Licensing. licenses at Bayer.
Under the development agreement, Bayer and its genetic partners have the ability to develop drugs that address unmet clinical needs.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
